Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, describes a trial comparing crizotinib and chemotherapy in patients with advancedALK-positive non-small cell lung cancer.
Based on single-arm phase I and phase II trials, Shaw says, it was known that crizotinib was efficacious in this space. The primary endpoint of the trial, progression-free survival, was met.
Crizotinib showed superiority with regard to progression-free survival compared with chemotherapy: 7.7 months versus 3.0 months. In addition, Shaw points out, crizotinib significantly increased response rates, from 20% to 65%. These data confirm the efficacy of crizotinib in this space.
Ruxolitinib Offers Durable Hematocrit Control, Low Thrombosis Risk in PV
May 30th 2024In an interview with Targeted Oncology, Aleksander L. Chojecki, MD, discussed findings from his research on hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib.
Read More